OXS007464

OXS007464 is a potent small molecule developed as a **tubulin binding agent** that drives the differentiation of acute myeloid leukemia (AML) cell lines. It has demonstrated improved potency and ADME (absorption, distribution, metabolism, and excretion) properties compared to earlier leads. OXS007464 induces differentiation of AML cells by upregulating CD11b cell surface expression and increasing the absolute number of CD11b positive cells, indicating true stimulation of cell differentiation. Analysis using the BioMAP phenotypic profiling platform suggests that its mechanism of action is **microtubule disruption**, similar to established microtubule-disrupting agents. OXS007464 has shown in vitro differentiation activity and in vivo efficacy in tumor models, and displays anti-proliferative effects on multiple primary human cell types without cytotoxicity at certain tested concentrations[1][7].